Overdiagnosis in mammography screening: A 45 year journey from shadowy idea to acknowledged reality: Alexandra Barratt summarises and debates overdiagnosis in breast cancer screening and discusses how myriad uncertainties might be resolved so we can move forward

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Barratt, Alexandra ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CONTRALATERAL PROPHYLACTIC MASTECTOMY; HEART DISEASE; HUMAN; INFORMATION; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; OVERDIAGNOSIS; PARTIAL MASTECTOMY; POLICY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; STANDARD; THREE DIMENSIONAL MAMMOGRAPHY; TWO DIMENSIONAL MAMMOGRAPHY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DIAGNOSTIC ERROR; EARLY DIAGNOSIS; FEMALE; RADIOGRAPHY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DIAGNOSTIC ERRORS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY;

EID: 84925728500     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h867     Document Type: Article

References (53)

1. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004;6(6):229-39.
2. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer 1977;39(6 Suppl):2772-82.
3. Tabár L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Gröntoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985;1:829-32.
4. Forrest P, Chamberlain J, Elton A, Evan K, Gravelle H, Hayes D, et al. Breast cancer screening. Report to the health ministers of England, Wales, Scotland and Northern Ireland. 1986. www.screening.org.uk/breastscreen/publications/forrest-report.pdf.
5. McPherson K. Screening for breast cancer-balancing the debate. BMJ 2010;340:c3106.
6. Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med 2014;370:1965-7.
7. Gøtzsche PC. Time to stop mammography screening? CMAJ 2011;183:1957-8.
8. McCartney M. Patients deserve the truth: health screening can do more harm than good. Guardian 2014 Jan 3. www.theguardian.com/science/blog/2014/jan/03/patients-truthhealth-screening-harm-good.
9. Orenstein P. Our feel-good war on breast cancer. New York Times 2013 Apr 25. www. nytimes.com/2013/04/28/magazine/our-feel-good-war-on-breast-cancer.html? pagewanted=all&-r=0.
10. Mammogram finds US TV reporter Robach's cancer. BBC 2013 Nov 12. www.bbc.com/ news/entertainment-arts-24910422.
11. Héry C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 2008;19:1009-18.
12. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013;108:2205-40.
13. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009;339:b2587.
14. Morrell S, Barratt A, Irwig L, Howard K, Biesheuvel C, Armstrong B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control 2010;21:275-82.
15. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 2014;348:g366.
16. Jørgensen KJ, Zahl PH, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark. A comparative study. BMC Womens Health 2009;9:36.
17. Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012;156(7):491-9.
18. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol 2007;8:1129-38.
19. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998-2005.
20. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685-92.
21. Hofvind S, Lee CI, Elmore JG. Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program. Breast Cancer Res Treat 2012;135:291-9.
22. Autier P, Boniol M, Middleton R, Doré JF, Héry C, Zheng T, et al. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol 2011;22:1726-35.
23. De Glas NA, de Craen AJ, Bastiaannet E, Op 't Land EG, Kiderlen M, van de Water W, et al. Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study. BMJ 2014;349:g5410.
24. Kerlikowske K. Epidemiology of ductal carcinoma in situ. Journal of the National Cancer Institute. Monographs 2010;2010:139-41.
25. Nederend J, Duijm LE, Louwman MW, Coebergh JW, Roumen RM, Lohle PN, et al. Impact of the transition from screen-film to digital screening mammography on interval cancer characteristics and treatment-a population based study from the Netherlands. Eur J Cancer 2014;50:31-9.
26. Hofvind S, Skaane P, Elmore JG, Sebuødegård S, Hoff SR, Lee CI. Mammographic performance in a population-based screening program: before, during, and after the transition from screen-film to full-field digital mammography. Radiology 2014;272:52-62.
27. Cancer Research UK. TNM breast cancer staging. www.cancerresearchuk.org/aboutcancer/ type/breast-cancer/treatment/tnm-breast-cancer-staging.
28. Feinleib M, Zelen M. Some pitfalls in the evaluation of screening programs. Arch Environ Health 1969;19:412-5.
29. Independent Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778-86.
30. Duffy SW, Tabar L, Olsen AH, Vitak B, Allgood PC, Chen TH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen 2010;17:25-30.
31. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013;6:CD001877.
32. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997;127:1023-8.
33. Zahl PH, Gøtzsche PC, Maehlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol 2011;12:1118-24.
34. Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 2015;150:9-16.
35. Hawley ST, Jagsi R, Morrow M, Janz NK, Hamilton A, Graff JJ, et al. Social and clinical determinants of contralateral prophylactic mastectomy. JAMA Surg 2014;149:582-9.
36. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987-98.
37. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
38. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004;22:4261-71.
39. Ganz PA. Psychological and social aspects of breast cancer. Oncology (Williston Park) 2008;22:642-50.
40. Duffy SW, Lynge E, Jonsson H, Ayyaz S, Olsen AH. Complexities in the estimation of overdiagnosis in breast cancer screening. Br J Cancer 2008;99:1176-8.
41. Zahl PH, Jørgensen KJ, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer 2013;109:2014-9.
42. Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ 2015;350:g7773.
43. ISRCTN registry. Surgery versus active monitoring for low risk ductal carcinoma in situ (DCIS). ISRCTN27544579. www.isrctn.com/ISRCTN27544579.
44. Ciatto S, Houssami N, Bernardi D, Caumo F, Pellegrini M, Brunelli S, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol 2013;14:583-9.
45. Houssami N, Macaskill P, Bernardi D, Caumo F, Pellegrini M, Brunelli S, et al. Breast screening using 2D-mammography or integrating digital breast tomosynthesis (3D-mammography) for single-reading or double-reading-evidence to guide future screening strategies. Eur J Cancer 2014;50:1799-807.
46. Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology 2013;267:47-56.
47. Irwig L, Houssami N, Armstrong B, Glasziou P. Evaluating new screening tests for breast cancer. BMJ 2006;332:678-9.
48. Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study. Radiology 2007;244:708-17.
49. Aschwanden C. Why I'm opting out of mammography. JAMA Int Med 2015;175:164-5.
50. Woloshin S, Schwartz LM. How a charity oversells mammography. BMJ 2012;345:e5132.
51. Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, et al. Women's views on overdiagnosis in breast cancer screening: a qualitative study. BMJ 2013;346:f158.
52. Waller J, Whitaker KL, Winstanley K, Power E, Wardle J. A survey study of women's responses to information about overdiagnosis in breast cancer screening in Britain. Br J Cancer 2014;111:1831-5.
53. Entwistle VA, Carter SM, Trevena L, Flitcroft K, Irwig L, McCaffery K, et al. Communicating about screening. BMJ 2008;337:a1591.